menu
    • menu
    [{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"}]

    Find Clinical Drug Pipeline Developments & Deals for Sumatriptan Succinate

    Menu

    Sumatriptan Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Towa Pharmaceutical

    Japan
    euroPLX 88 Lisbon
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothTowa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Acquired Approval for Manufacturing and Marketing Generic Drugs

    Details : Sumatriptan is a generic version of imigran which is indicated for the treatment of acute treatment of migraine with or without aura in adults.

    Product Name : Sumatriptan Tablets

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 15, 2024

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    Towa Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Nuvo Pharmaceuticals

    Canada arrow
    BePharma
    Not Confirmed

    Nuvo Pharmaceuticals

    Canada arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naproxen Sodium,Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Orion Corporation

    Deal Size : $0.6 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets

    Details :

    Product Name : Suvexx

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 15, 2023

    Lead Product(s) : Naproxen Sodium,Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Orion Corporation

    Deal Size : $0.6 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Upsher-Smith Laboratories

    U.S.A arrow
    BePharma
    Not Confirmed

    Upsher-Smith Laboratories

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Tonix Pharmaceuticals Holding Corp

    Deal Size : $25.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upshe...

    Details : The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.

    Product Name : Zembrace SymTouch

    Product Type : Other Small Molecule

    Upfront Cash : $22.0 million

    June 26, 2023

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Tonix Pharmaceuticals Holding Corp

    Deal Size : $25.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Upsher-Smith Laboratories

    U.S.A arrow
    BePharma
    Not Confirmed

    Upsher-Smith Laboratories

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Tonix Pharmaceuticals Holding Corp

    Deal Size : $25.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

    Details : Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.

    Product Name : Zembrace SymTouch

    Product Type : Other Small Molecule

    Upfront Cash : $22.0 million

    March 07, 2023

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Tonix Pharmaceuticals Holding Corp

    Deal Size : $25.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Cipla

    India arrow
    BePharma
    Not Confirmed

    Cipla

    India arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline’s IMITREX®

    Details : Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex® Nasal Spray.

    Product Name : Sumatriptan-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 03, 2021

    Lead Product(s) : Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Miravo Healthcare

    Canada arrow
    BePharma
    Not Confirmed

    Miravo Healthcare

    Canada arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naproxen Sodium,Sumatriptan

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Orion Corporation

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Miravo Healthcare Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select ...

    Details :

    Product Name : Suvexx

    Product Type : Other Small Molecule

    Upfront Cash : $2.0 million

    December 21, 2020

    Lead Product(s) : Naproxen Sodium,Sumatriptan

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Orion Corporation

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth